Magistretti M J, Conti M, Cristoni A
Research and Development Laboratories, Inverni della Beffa S.p.A., Milan, Italy.
Arzneimittelforschung. 1988 May;38(5):686-90.
The antiulcer effects of 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-1-benzopyrylium chloride (IdB 1027) were assessed in various experimental models. Given orally, IdB 1027 antagonized gastric ulcerations induced by pylorus ligation, stress, nonsteroidal antiinflammatory drugs, ethanol, reserpine, histamine and duodenal ulceration induced by mercaptamine (cysteamine). Moreover it antagonized chronic gastric ulcers induced by acetic acid. Given intraperitoneally, it was more potent than after oral administration. IdB 1027 did not affect gastric secretion in pylorus-ligated rats and increased gastric mucus in normal animals both in the absence and in the presence of indometacin treatment. Tolerability was very good. These results indicate that IdB 1027 possesses a promising antiulcer activity, probably by potentiating the defensive barriers of the gastrointestinal mucosa.
在多种实验模型中评估了氯化3,5,7 - 三羟基 - 2 - (3,4 - 二羟基苯基)-1 - 苯并吡喃鎓（IdB 1027）的抗溃疡作用。口服给药时，IdB 1027可对抗幽门结扎、应激、非甾体抗炎药、乙醇、利血平、组胺诱导的胃溃疡以及半胱胺（巯基乙胺）诱导的十二指肠溃疡。此外，它还能对抗乙酸诱导的慢性胃溃疡。腹腔注射给药时，其效力比口服给药更强。IdB 1027对幽门结扎大鼠的胃分泌无影响，在正常动物中，无论是否存在吲哚美辛治疗，它均可增加胃黏液。耐受性非常好。这些结果表明，IdB 1027可能通过增强胃肠道黏膜的防御屏障而具有有前景的抗溃疡活性。
